Drug Approval | April 30, 2026
Wanbury's Patalganga site clears Korea FDA inspection with zero observations
Patalganga plant received zero observation from USFDA earlier
Patalganga plant received zero observation from USFDA earlier
The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets
After Phase 3 results show major hair regrowth gains
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The submission is backed by positive results from the Phase 3 AFFIRM study
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Aims to boost speed & precision in patient care
Subscribe To Our Newsletter & Stay Updated
